For HER2/PD-1 or HER2/PD-L1 bispecific formats, co-localizing checkpoint inhibition at the HER2-expressing tumour sites may further enhance recruitment of cytotoxic T-cells and NK cells (as described in Section 4.3). This evidence concerns the gene ERBB2 and neoplasm.